睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07308106,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Participants with histologically or cytologically confirmed NSCLC.

    入选标准第 2 条

  3. Toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1.

    排除标准第 8 条

    Participants who have received systemic corticosteroid therapy with > 10 mg/day of prednisone or other immunosuppressive drugs within 2 weeks before the first dose of study treatment.

    排除标准第 16 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose.

    入选标准第 5 条

  5. Participants with other malignant tumors within 3 years prior to the first dose.

    排除标准第 2 条

    Positive test for human immunodeficiency virus (HIV) or a medical history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.

    排除标准第 12 条

  6. Pregnant or breastfeeding women.

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07308106,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF).
  2. Participants with histologically or cytologically confirmed NSCLC.
  3. Locally advanced or metastatic NSCLC with MET Abnormalities that has progressed after standard therapy.
  4. At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose.
  6. Life expectancy ≥ 3 months as assessed by the investigator.
  7. Adequate organ and bone marrow function.
  8. Male and female participants must agree to use highly effective methods of contraception during the study treatment period.
  9. Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol.

排除标准:Exclusion Criteria:

  1. Participants with known active central nervous system (CNS) metastasis, and/or carcinomatous meningitis, brainstem metastasis, metastases to spinal cord, or spinal cord compression.
  2. Participants with other malignant tumors within 3 years prior to the first dose.
  3. Presence of any of the following cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
  4. Presence of severe and/or uncontrolled concomitant diseases.
  5. Participants with a history of interstitial lung disease (ILD) or a history of non-infectious pneumonitis.
  6. Clinically severe lung damage due to complications of lung disorder.
  7. Risk of esophagotracheal fistula or esophagopleural fistula, or tumor invasion or compression of surrounding vital organs and blood vessels.
  8. Toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1.
  9. Known active pulmonary tuberculosis.
  10. Known history of allogeneic organ transplant or allogeneic hematopoietic stem cell transplant.
  11. Active hepatitis B and hepatitis C.
  12. Positive test for human immunodeficiency virus (HIV) or a medical history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
  13. Known allergy or hypersensitivity to SKB571 or its excipients; or a history of severe allergy to other monoclonal antibodies.
  14. Participants who have undergone major surgery within 4 weeks before the first dose or are expected to require major surgery during the study.
  15. Serious infection within 4 weeks before the first dose.
  16. Participants who have received systemic corticosteroid therapy with > 10 mg/day of prednisone or other immunosuppressive drugs within 2 weeks before the first dose of study treatment.
  17. Participants who have received a live vaccine within 30 days before the first dose, or plan to receive a live vaccine during the study.
  18. Pregnant or breastfeeding women.
  19. Have local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors.
  20. Any condition that, in the investigator's opinion, interferes with the evaluation of study treatment, participant safety, or interpretation of study results, or any other condition that the investigator deems unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT07308106, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07308106,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07308106